Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert

Efficacy and safety of ab-interno canaloplasty (ABiC) for the treatment of glaucoma

Search Title by author or title

Session Details

Session Title: Presented Poster Session: Glaucoma

Session Date/Time: Sunday 11/09/2016 | 15:00-16:30

Paper Time: 16:10

Venue: Poster Village: Pod 3

First Author: : N.Koerber GERMANY

Co Author(s): :                  

Abstract Details


To evaluate the efficacy and safety of ABiC in pseudophakic patients with primary open-angle glaucoma (POAG)


Augencentrum Köln-Porz, Germany


Patients (mean age, 76 years; range, 66-83 years) underwent ABiC using the iTrack™ 250-micron microcatheter (Ellex Medical Lasers Pty Ltd, Adelaide, Australia) to circumferentially viscodilate and intubate Schlemm’s canal without placement of a tensioning suture. The primary endpoints were mean intraocular pressure (IOP) and mean number of glaucoma medications at 1, 3, 6, 9 and 12 months postoperative.


Mean IOP reduced from 18.5 ± 3.44 mm Hg preoperatively to 14.88 ± 2.82 mm Hg (n=17), 13.80 ± 2.05 (n=12), 14.57 ± 2.59 mm Hg (n=9) and 15.47 ± 2.42 (n=6) at 1, 3, 6 and 9 months postoperatively. 12-month data for two patients showed that their IOP was 16 mm Hg and 13 mm Hg, respectively. The mean number of medications was reduced from 2.4 preoperatively to 0.25 at the last follow-up visit. Limited descemetolysis near the limbus during the dilatation of Schlemm`s canal occurred in one patient. No other adverse events were reported.


Initial findings from this study indicate that ABiC lowers IOP and medication dependency. Long-term follow-up in a large patient cohort is required to confirm the efficacy of this minimally-invasive glaucoma procedure.

Financial Disclosure:


Back to previous